Holen Sie sich die Stockscreener-App
13.74
1.22%
-0.17
Schlusskurs vom Vortag:
$13.91
Offen:
$14.095
24-Stunden-Volumen:
3.69M
Relative Volume:
0.54
Marktkapitalisierung:
$4.45B
Einnahmen:
$79.21M
Nettoeinkommen (Verlust:
$-143.96M
KGV:
-28.65
EPS:
-0.4796
Netto-Cashflow:
$-189.60M
1W Leistung:
+8.19%
1M Leistung:
+20.95%
6M Leistung:
+290.34%
1J Leistung:
+129.77%
1-Tages-Spanne:
$13.66
$14.30
1-Wochen-Bereich:
$12.38
$15.02
52-Wochen-Spanne:
$2.745
$15.02
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
13.74 | 4.12B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment - marketscreener.com
Total equity of AbCellera Biologics, Inc. – HAN:8QQ - TradingView
JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target - Moomoo
AbCellera Biologics, Inc. Actuals & Estimates (HAN:8QQ) - TradingView
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? - TradingView
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17 - Moomoo
ABCL Initiated Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
Why is Abcellera Biologics stock climbing today? By Investing.com - Investing.com Canada
Abcellera Biologics stock hits 52-week high at 13.23 USD - Investing.com
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13 - moomoo.com
ABCL Reinstated by Goldman Sachs -- Neutral Rating with Price Ta - GuruFocus
AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs - Moomoo
Goldman Sachs resumes AbCellera stock coverage with neutral rating - Investing.com
Goldman Sachs resumes AbCellera stock coverage with neutral rating By Investing.com - Investing.com Canada
ABCL Looks 201.0% Overvalued on GF Value™ - GuruFocus
AbCellera Biologics Inc. (ABCL) Options Chain - Yahoo Finance
ABCL Stock Price and Chart — NASDAQ:ABCL - tradingview.com
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - Yahoo Finance
ABCL Should I Buy - Intellectia AI
AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech Gem With A 34% Upside Potential - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsMNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews
Abcellera Biologics stock hits 52-week high at 12.58 USD By Investing.com - Investing.com Australia
Abcellera Biologics stock hits 52-week high at 12.58 USD - Investing.com
Abcellera Biologics Inc (ABCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AbCellera to present phase 2 data on menopause treatment drug By Investing.com - Investing.com Nigeria
ABCL Looks 171.0% Overvalued on GF Value™ - gurufocus.com
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 - Investing News Network
AbCellera to present phase 2 data on menopause treatment drug - Investing.com
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes By Investing.com - Investing.com South Africa
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes - Investing.com
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
AbCellera Biologics (ABCL) Q4 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative
Historical Data for AbCellera Biologics Inc. Tokenized Stock (Robinhood) in USD - CryptoRank
What'sGoing On With AbCellera Biologics Stock On Tuesday? - Benzinga
ABCL Stock Surges As ABCL635 Data Reset Wall Street Expectations - StocksToTrade
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Punaises (dD09m2oJ3D) - Mshale
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain? - simplywall.st
Abcellera director John S. Montalbano acquires common shares worth $110,300 - Bitget
AbCellera Biologics Director John S. Montalbano Acquires 10,000 Shares on August 18, 2026 - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Montalbano John S. - Moomoo
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):